Career pressures and race to financial wellbeing is changing the trend of pregnancy age in past few years. Due to this, the term ‘Elderly Primagravida’ is commonly read on the medical report of expectant mothers especially in the US and Europe. In the language of obstetrics, the word ‘Elderly’ depicts the age of pregnant woman who is 35 or over and ‘Primagravida’ refers to first pregnancy.
According to the report by Centers for Disease Control and Prevention (CDC), women delivering first child at the age in between 35 to 39 climbed over 40% in eight states of the US—North Dakota, New York, Oregon, Rhode Island, South Dakota, Washington and Washington, D.C. Similarly, the rate jumped to more than 20% in other 30 states.
This rising trend of late pregnancies—35 or over—is strongly pushing the demand for Prenatal Genetic Tests (PGT) in developed economies. It is because late pregnancy increases the risk of chromosomal anomalies in the fetus resulting birth of a child with an extra copy of a chromosome which leads to syndromes in child such as Down’s syndrome, Edward’s syndrome and Patau syndrome.
Of the various Prenatal Genetic Tests—Non-invasive Prenatal Testing (NIPT), Invasive Prenatal Testing, Carrier Screening Test and Miscarriage Test—the NIPT is featuring as most promising test for aforementioned syndromes along with Fragile X syndrome.
In order to test genetic abnormalities, NIPT uses the DNA collected from mother’s bloodstream which (blood) has the fragments of growing fetus’s DNA. It has 99% accuracy if performed in the first trimester. Moreover, performing NIPT tests means reducing invasive procedures significantly as a result it (NIPT) has positive impact on patient compliance, too.
However, in case of a deduced risk of chromosomal aneuploidy through NIPT test, certain invasive tests such as Amniocentesis and Chorionic Villus sampling (CVS) is also prescribed. The test requires a tissue sample from the mother for better analysis.
Due to the rise in elderly pregnancies rate, most of the countries in Western Europe like the UK, France, Spain, Switzerland, etc. have considered screening of chromosomal anomalies as a necessary part of prenatal testing. As a result, the market of PGT is gradually inflating in the region.
Besides regulatory landscapes, governments’ collaboration with leading market players of PGT—Natera, Sequenom, Ariosa, etc.—to provide prenatal tests to its public at cost-effective price is also driving PGT market towards growth stage form startup phase.
This evolving market of PGT in Europe is also presenting lucrative opportunity for key market participants involved in NIPT tests segment. It is because the number of competitors is very low at present, around five, and the segment (NIPT) is projected to occupy 74% of total PGT market reaching over US $450 million from around US $270 million by the end of 2021.
For more information on “Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021” please visit https://store.frost.com/growth-opportunities-in-european-prenatal-genetic-testing-market-forecast-to-2021.html
Subarna Poudel is a researcher with Frost & Sullivan. He can be reached at firstname.lastname@example.org
Sapan Agarwal drives content and marketing for Frost & Sullivan. Sapan is based out of Kuala Lumpur Malaysia and can be reached at email@example.com | +603 6204 5830